Blood Pressure
|
Pulse
|
Weight
|
Temperature
|
Glucose
|
Diagnosis
|
Medication
|
Sick Leave
|
Date
|
Actions |
171/87
|
67
|
97kg
|
36.4
|
|
OA
|
volt inj/dcf prednsn
|
2020/08/05
|
0
|
Details
|
159/84
|
80
|
112.6
|
36.6
|
6.8
|
OA
|
VOLT INJ DCF SALTPYN
RIDQA ENAP AMT 5 / FUROSEMIDE LSLOWK
|
2020/09/13
|
0
|
Details
|
170/90
|
71
|
112.3
|
35.5
|
4.2
|
|
|
2020/10/15
|
|
Details
|
170/90
|
71
|
112.3
|
35.5
|
4.2
|
OA
HPT
|
RIDQ/AMT10/DCF ALCOPP/MAGASSIL
|
2020/10/15
|
0
|
Details
|
122/75
|
77
|
111,3
|
36.5
|
7,3
|
OA
HPT
|
VOLT INJ DCF SALTPYN UM SCALCIUM
RIDAQ/ENAP/AMT5
|
2020/11/05
|
0
|
Details
|
185/82
|
77
|
107.7
|
36.0
|
6.7mmol
|
MIGRAINE ULCERS
|
VOLT INJ CIMETIDINE CIFRAN TREPLN
|
2022/06/10
|
0
|
Details
|
173/74
|
88
|
107.8
|
36.3
|
7.8mmol/l
|
ULCERS
|
VOLT INJ MAGASIL CIMETIDEN
|
2022/06/13
|
0
|
Details
|
182/97
|
73
|
NA
|
36.3
|
6.4
|
OA/HPT
|
DICL INJ, RIDAQ, ENAP, AMLODAC, PRED, SALTER, TRAM, MACROPEN, CLEAR COUGH
SCRIPT COLCHICINE
URIC ACID
|
2022/07/27
|
0
|
Details
|
148/80
|
74
|
102.6KG
|
36.2
|
|
ALLERGY OA
|
VOLT INJ
|
2022/07/29
|
0
|
Details
|
139/69
|
75
|
NA
|
36,4
|
8.0mmol/L
|
OA
CELLULITIS
|
VOLT INJ D CF TRAMADOL TREPLN UMS CANEX T PYRDXBN
|
2022/08/13
|
0
|
Details
|
169/82
|
65
|
106.7
|
36.0
|
4.8MMOL/L
|
OA
|
VOLT INJ DCF SALTPYN BETAPAM TRAMADOL
|
2023/11/28
|
0
|
Details
|
164/84
|
71
|
106.7KG
|
36.3
|
4.9mmol/l
|
- CCF
- Arthritis
|
- Furosemide 40mg imi stat
- Dexona + Voltaren
- Rub-rub
- Refer to hospital
|
2024/03/21
|
0
|
Details
|
211/82
|
73
|
N/A
|
36.4
|
5.7mmol/l
|
HPT HEAD INJURY
|
EDH ED SALTPYN DEEP ACERTION DDVF SALTPYN VOKT IUNJ
|
2024/08/05
|
0
|
Details
|
130/82
|
73
|
104.4KG
|
36.5
|
9.8
|
OA/CELLULITIS
|
DICL INJ, MACROPEN, FLAGYL, RHIN, RUB, CHLORA, BETAPAM, TREP, SALTER, CALCIUM, PYRIDOXINE, MVT
|
2025/01/15
|
0
|
Details
|
155/70
|
70
|
105.4kg
|
36.6
|
7.3mmol/l
|
OA
|
DICLO IMI
SALTERPAIN, DICLO, ASCORBIC ACID
|
2025/03/22
|
0
|
Details
|
132/67
|
81
|
107KG
|
36.6
|
6.3mmol/l
|
OA ULC RR
|
VOLT J DCF TRAMAMDOL UMS PREDSNSN
|
2025/05/15
|
0
|
Details
|